Provention Bio Gets FDA OK for Diabetes Drug
November 17 2022 - 5:39PM
Dow Jones News
By Josh Beckerman
Provention Bio Inc. said the U.S. Food and Drug Administration
approved the Biologics License Application for TZIELD as a
treatment to delay the onset of Stage 3 type 1 diabetes in patients
ages 8 and up with Stage 2 type 1 diabetes.
Shares were up 1 cent after hours st $8.25 before the stock was
halted due to pending news.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 17, 2022 18:24 ET (23:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Provention Bio Inc (NASDAQ): 0 recent articles
More Provention Bio Inc News Articles